Last reviewed · How we verify

GEn (XP13512) — Competitive Intelligence Brief

GEn (XP13512) (GEn (XP13512)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gabapentin prodrug / Anticonvulsant. Area: Neurology.

phase 3 Gabapentin prodrug / Anticonvulsant LAT1 (Large Neutral Amino Acid Transporter 1) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

GEn (XP13512) (GEn (XP13512)) — XenoPort, Inc.. XP13512 is a prodrug of gabapentin that uses a novel amino acid transporter-mediated delivery system to enhance absorption and bioavailability in the gastrointestinal tract.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
GEn (XP13512) TARGET GEn (XP13512) XenoPort, Inc. phase 3 Gabapentin prodrug / Anticonvulsant LAT1 (Large Neutral Amino Acid Transporter 1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Gabapentin prodrug / Anticonvulsant class)

  1. XenoPort, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GEn (XP13512) — Competitive Intelligence Brief. https://druglandscape.com/ci/gen-xp13512. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: